<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36906">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02019121</url>
  </required_header>
  <id_info>
    <org_study_id>521455</org_study_id>
    <nct_id>NCT02019121</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine and Renal Transplants</brief_title>
  <official_title>Dexmedetomidine and Renal Transplants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators aim to retrospectively research patients undergoing renal transplants that
      received dexmedetomidine perioperatively to see if dexmedetomidine use protects renal
      function.  Investigators hope to elucidate any association between renal transplant patients
      and perioperative dexmedetomidine administration, these include (but are not limited to)
      UOP, Cr/GFR, morbidity, mortality, in hospital complications and failure rate.
      Investigators will research both living and cadaveric renal transplants.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Cr/GFR improvement, postoperative mortality/morbidity (within 30 days) and overall complications</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Graft failure, length of hospital stay (LOS), length of ICU stay, re-admission rate, infections, pulmonary complications.</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>length of intubation time, and length of ventilation time</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Renal Transplants</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Renal transplant patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria: Patients greater than or equal to 18 years old that underwent renal
        transplant at UC Davis Medical Center -

        Exclusion Criteria: Patients that did not undergo renal transplants and patients less than
        18 years old will be excluded from the study.

        -
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UC Davis Health System</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 17, 2013</lastchanged_date>
  <firstreceived_date>November 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Davis</investigator_affiliation>
    <investigator_full_name>Hong Liu, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
